Novo Nordisk Alzheimer's Trials Fail to Meet Primary Endpoint
Ticker: NONOF · Form: 6-K · Filed: Nov 24, 2025 · CIK: 353278
Sentiment: bearish
Topics: clinical-trial-failure, alzheimers, pipeline-update
TL;DR
Novo Nordisk's Alzheimer's drug Evoke/Evoke+ failed Phase 3, no significant reduction in disease progression.
AI Summary
Novo Nordisk announced on November 24, 2025, that its Phase 3 Evoke and Evoke+ trials for an Alzheimer's disease treatment did not show a statistically significant reduction in disease progression over two years. The trials were randomized and double-blinded, evaluating the drug's efficacy in early-stage symptomatic Alzheimer's disease.
Why It Matters
This outcome represents a significant setback for Novo Nordisk's Alzheimer's pipeline and could impact investor confidence in their ability to diversify beyond their core diabetes and obesity franchises.
Risk Assessment
Risk Level: high — The failure of late-stage trials for a major disease indication like Alzheimer's poses a substantial risk to the company's future growth prospects and pipeline.
Key Players & Entities
- Novo Nordisk A/S (company) — Registrant and filer of the report
- Evoke (trial) — Phase 3 Alzheimer's disease trial
- Evoke+ (trial) — Phase 3 Alzheimer's disease trial
- November 24, 2025 (date) — Date of the announcement and filing
FAQ
What was the primary outcome of the Evoke and Evoke+ Phase 3 trials?
The trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression.
When were the top-line results from the Evoke and Evoke+ trials announced?
The top-line results were announced on November 24, 2025.
What stage of Alzheimer's disease were the Evoke and Evoke+ trials designed to treat?
The trials were for early-stage symptomatic Alzheimer's disease.
What type of trials were Evoke and Evoke+?
They were randomized, double-blinded Phase 3 trials.
What is the filing form type and date?
The filing form is a 6-K, filed on November 24, 2025.
Filing Stats: 1,103 words · 4 min read · ~4 pages · Grade level 14.3 · Accepted 2025-11-24 07:23:52
Filing Documents
- f6k_112425.htm (6-K) — 25KB
- logo.jpg (GRAPHIC) — 76KB
- ca.jpg (GRAPHIC) — 24KB
- 0001171843-25-007519.txt ( ) — 164KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized. Date: November 24, 2025 NOVO NORDISK A/S Maziar Mike Doustdar Chief Executive Officer